Publications - Wilma L. Lingle, Ph.D.

Back to research profile

  1. Perez EA, Dueck AC, McCullough AE, Chen B, Geiger XJ, Jenkins RB, Lingle WL, Davidson NE, Martino S, Kaufman PA, Kutteh LA, Sledge GW, Harris LN, Gralow JR, Reinholz MM. Impact of PTEN Protein Expression on Benefit From Adjuvant Trastuzumab in Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the North Central Cancer Treatment Group N9831 Trial. J Clin Oncol. 2013 May 06. [Epub ahead of print]
    View PubMed
  2. Li Y, Tang H, Sun Z, Bungum AO, Edell ES, Lingle WL, Stoddard SM, Zhang M, Jen J, Yang P, Wang L. Network-based approach identified cell cycle genes as predictor of overall survival in lung adenocarcinoma patients. Lung Cancer. 2013 Apr; 80(1):91-8. Epub 2013 Jan 26.
    View PubMed
  3. Perez EA, Press MF, Dueck AC, Jenkins RB, Kim C, Chen B, Villalobos I, Paik S, Buyse M, Wiktor AE, Meyer R, Finnigan M, Zujewski J, Shing M, Stern HM, Lingle WL, Reinholz MM, Slamon DJ. Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005). Breast Cancer Res Treat. 2013 Feb; 138(1):99-108. Epub 2013 Feb 19.
    View PubMed
  4. D'Assoro AB, Liu T, Quatraro C, Amato A, Opyrchal M, Leontovich A, Ikeda Y, Ohmine S, Lingle W, Suman V, Ecsedy J, Iankov I, Di Leonardo A, Ayers-Inglers J, Degnim A, Billadeau D, McCubrey J, Ingle J, Salisbury JL, Galanis E. The mitotic kinase Aurora-A promotes distant metastases by inducing epithelial-to-mesenchymal transition in ERalpha(+) breast cancer cells. Oncogene. 2013 Jan 21. [Epub ahead of print]
    View PubMed
  5. Isham CR, Bossou AR, Negron V, Fisher KE, Kumar R, Marlow L, Lingle WL, Smallridge RC, Sherman EJ, Suman VJ, Copland JA, Bible KC. Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer. Sci Transl Med. 2013 Jan 2; 5(166):166ra3.
    View PubMed
  6. Hawse JR, Subramaniam M, Cicek M, Wu X, Gingery A, Grygo SB, Sun Z, Pitel KS, Lingle WL, Goetz MP, Ingle JN, Spelsberg TC. Endoxifen's molecular mechanisms of action are concentration dependent and different than that of other anti-estrogens. PLoS One. 2013; 8(1):e54613. Epub 2013 Jan 28.
    View PubMed
  7. Kolbert CP, Feddersen RM, Rakhshan F, Grill DE, Simon G, Middha S, Jang JS, Simon V, Schultz DA, Zschunke M, Lingle W, Carr JM, Thompson EA, Oberg AL, Eckloff BW, Wieben ED, Li P, Yang P, Jen J. Multi-platform analysis of microRNA expression measurements in RNA from fresh frozen and FFPE tissues. PLoS One. 2013; 8(1):e52517. Epub 2013 Jan 31.
    View PubMed
  8. Sideras K, Dueck AC, Hobday TJ, Rowland KM Jr, Allred JB, Northfelt DW, Lingle WL, Behrens RJ, Fitch TR, Nikcevich DA, Perez EA. North central cancer treatment group (NCCTG) N0537: phase II trial of VEGF-trap in patients with metastatic breast cancer previously treated with an anthracycline and/or a taxane. Clin Breast Cancer. 2012 Dec; 12(6):387-91. Epub 2012 Oct 17.
    View PubMed
  9. Harrington SC, Weroha SJ, Reynolds C, Suman VJ, Lingle WL, Haluska P. Quantifying insulin receptor isoform expression in FFPE breast tumors. Growth Horm IGF Res. 2012 Jun-Aug; 22(3-4):108-15. Epub 2012 Apr 30.
    View PubMed
  10. Wu X, Subramaniam M, Negron V, Cicek M, Reynolds C, Lingle WL, Goetz MP, Ingle JN, Spelsberg TC, Hawse JR. Development, characterization, and applications of a novel estrogen receptor beta monoclonal antibody. J Cell Biochem. 2012 Feb; 113(2):711-23.
    View PubMed
  11. Ghosh K, Brandt KR, Reynolds C, Scott CG, Pankratz VS, Riehle DL, Lingle WL, Odogwu T, Radisky DC, Visscher DW, Ingle JN, Hartmann LC, Vachon CM. Tissue composition of mammographically dense and non-dense breast tissue. Breast Cancer Res Treat. 2012 Jan; 131(1):267-75. Epub 2011 Aug 30.
    View PubMed
  12. Strizzi L, Hardy KM, Margaryan NV, Hillman DW, Seftor EA, Chen BY, Geiger XJ, Thompson EA, Lingle WL, Andorfer CA, Perez EA, Hendrix MJC. Potential for the embryonic morphogen nodal as a prognostic and predictive biomarker in breast cancer. Breast Cancer Res. 2012; 14(3):R75.
  13. Reinholz MM, Kitzmann KA, Tenner K, Hillman D, Dueck AC, Hobday TJ, Northfelt DW, Moreno-Aspitia A, Roy V, LaPlant B, Allred JB, Stella PJ, Lingle WL, Perez EA. Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group trials, N0234/336/436/437. Clin Cancer Res. 2011 Nov 15; 17(22):7183-93. Epub 2011 Oct 05.
    View PubMed
  14. Khurana A, Liu P, Mellone P, Lorenzon L, Vincenzi B, Datta K, Yang B, Linhardt RJ, Lingle W, Chien J, Baldi A, Shridhar V. HSulf-1 modulates FGF2- and hypoxia-mediated migration and invasion of breast cancer cells. Cancer Res. 2011 Mar 15; 71(6):2152-61. Epub 2011 Jan 25.
    View PubMed
  15. Perez EA, Jenkins RB, Dueck AC, Wiktor AE, Bedroske PP, Anderson SK, Ketterling RP, Sukov WR, Kanehira K, Chen B, Geiger XJ, Andorfer CA, McCullough AE, Davidson NE, Martino S, Sledge GW, Kaufman PA, Kutteh LA, Gralow JR, Harris LN, Ingle JN, Lingle WL, C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial. J Clin Oncol. 2011 Feb 20; 29(6):651-9. Epub 2011 Jan 18.
    View PubMed
  16. Vachon CM, Sasano H, Ghosh K, Brandt KR, Watson DA, Reynolds C, Lingle WL, Goss PE, Li R, Aiyar SE, Scott CG, Pankratz VS, Santen RJ, Ingle JN. Aromatase immunoreactivity is increased in mammographically dense regions of the breast. Breast Cancer Res Treat. 2011 Jan; 125(1):243-52. Epub 2010 Jun 05.
    View PubMed
  17. Jang JS, Simon VA, Feddersen RM, Rakhshan F, Schultz DA, Zschunke MA, Lingle WL, Kolbert CP, Jen J. Quantitative miRNA expression analysis using fluidigm microfluidics dynamic arrays. BMC Genomics. 2011; 12:144. Epub 2011 Mar 09.
    View PubMed
  18. Lukasiewicz KB, Greenwood TM, Negron VC, Bruzek AK, Salisbury JL, Lingle WL. Control of centrin stability by Aurora A. PLoS One. 2011; 6(6):e21291. Epub 2011 Jun 23.
    View PubMed
  19. Wampfler JA, Aubry MC, Yang P, Riehle DL, Dilara Savci-Heijink C, Mandrekar S, Lingle WL. Determining the optimal numbers of cores based on tissue microarray antibody assessment in non-small cell lung cancer. Journal of Cancer Science and Therapy. 2011; 3(6):120-4.
  20. Wu X, Subramaniam M, Grygo SB, Sun Z, Negron V, Lingle WL, Goetz MP, Ingle JN, Spelsberg TC, Hawse JR. Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen. Breast Cancer Res. 2011; 13(2):R27. Epub 2011 Mar 10.
    View PubMed
  21. Perez EA, Reinholz MM, Hillman DW, Tenner KS, Schroeder MJ, Davidson NE, Martino S, Sledge GW, Harris LN, Gralow JR, Dueck AC, Ketterling RP, Ingle JN, Lingle WL, Kaufman PA, Visscher DW, Jenkins RB. HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol. 2010 Oct 1; 28(28):4307-15. Epub 2010 Aug 09.
    View PubMed
  22. Huang W, Reinholz M, Weidler J, Yolanda L, Paquet A, Whitcomb J, Lingle W, Jenkins RB, Chen B, Larson JS, Tan Y, Sherwood T, Bates M, Perez EA. Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assay. Am J Clin Pathol. 2010 Aug; 134(2):303-11.
    View PubMed
  23. Reinholz MM, Zinnen SP, Dueck AC, Dingli D, Reinholz GG, Jonart LA, Kitzmann KA, Bruzek AK, Negron V, Abdalla AK, Arendt BK, Croatt AJ, Sanchez-Perez L, Sebesta DP, Lonnberg H, Yoneda T, Nath KA, Jelinek DF, Russell SJ, Ingle JN, Spelsberg TC, Dixon HB, A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites. Bone. 2010 Jul; 47(1):12-22. Epub 2010 Mar 15.
    View PubMed
  24. Litzow MR, Peethambaram PP, Safgren SL, Keeney GL, Ansell SM, Dispenzieri A, Elliott MA, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Micallef IN, Porrata LF, Lingle WL, Hartmann LC, Frost MH, Barrette BA, Long HJ, Suman VJ, Reid JM, Ames MM, Kaufmann Phase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma. Bone Marrow Transplant. 2010 Mar; 45(3):490-7. Epub 2009 Aug 03.
    View PubMed
  25. Holmes AL, Wise SS, Pelsue SC, Aboueissa AM, Lingle W, Salisbury J, Gallagher J, Wise JP Sr. Chronic exposure to zinc chromate induces centrosome amplification and spindle assembly checkpoint bypass in human lung fibroblasts. Chem Res Toxicol. 2010 Feb 15; 23(2):386-95.
    View PubMed
  26. Reinholz MM, Eckel-Passow JE, Anderson SK, Asmann YW, Zschunke MA, Oberg AL, McCullough AE, Dueck AC, Chen B, April CS, Wickham-Garcia E, Jenkins RB, Cunningham JM, Jen J, Perez EA, Fan JB, Lingle WL. Expression profiling of formalin-fixed paraffin-embedded primary breast tumors using cancer-specific and whole genome gene panels on the DASL(R) platform. BMC Med Genomics. 2010; 3:60. Epub 2010 Dec 20.
    View PubMed
  27. Critchley-Thorne RJ, Miller SM, Taylor DL, Lingle WL. Applications of cellular systems biology in breast cancer patient stratification and diagnostics. Comb Chem High Throughput Screen. 2009 Nov; 12(9):860-9.
    View PubMed
  28. Lukasiewicz KB, Lingle WL. Aurora A, centrosome structure, and the centrosome cycle. Environ Mol Mutagen. 2009 Oct; 50(8):602-19.
    View PubMed
  29. Pei H, Li L, Fridley BL, Jenkins GD, Kalari KR, Lingle W, Petersen G, Lou Z, Wang L. FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell. 2009 Sep 8; 16(3):259-66.
    View PubMed
  30. Fu Z, Regan K, Zhang L, Muders MH, Thibodeau SN, French A, Wu Y, Kaufmann SH, Lingle WL, Chen J, Tindall DJ. Deficiencies in Chfr and Mlh1 synergistically enhance tumor susceptibility in mice. J Clin Invest. 2009 Sep; 119(9):2714-24. Epub 2009 Aug 17.
    View PubMed
  31. Chien J, Fan JB, Bell DA, April C, Klotzle B, Ota T, Lingle WL, Gonzalez Bosquet J, Shridhar V, Hartmann LC. Analysis of gene expression in stage I serous tumors identifies critical pathways altered in ovarian cancer. Gynecol Oncol. 2009 Jul; 114(1):3-11. Epub 2009 May 01.
    View PubMed
  32. Reinholz MM, Bruzek AK, Visscher DW, Lingle WL, Schroeder MJ, Perez EA, Jenkins RB. Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response. Lancet Oncol. 2009 Mar; 10(3):267-77.
    View PubMed
  33. Moreno-Aspitia A, Morton RF, Hillman DW, Lingle WL, Rowland KM Jr, Wiesenfeld M, Flynn PJ, Fitch TR, Perez EA. Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. J Clin Oncol. 2009 Jan 1; 27(1):11-5. Epub 2008 Dec 01.
    View PubMed
  34. Balan V, Nangia-Makker P, Schwartz AG, Jung YS, Tait L, Hogan V, Raz T, Wang Y, Yang ZQ, Wu GS, Guo Y, Li H, Abrams J, Couch FJ, Lingle WL, Lloyd RV, Ethier SP, Tainsky MA, Raz A. Racial disparity in breast cancer and functional germ line mutation in galectin-3 (rs4644): a pilot study. Cancer Res. 2008 Dec 15; 68(24):10045-50.
    View PubMed
  35. McCollum AK, Lukasiewicz KB, Teneyck CJ, Lingle WL, Toft DO, Erlichman C. Cisplatin abrogates the geldanamycin-induced heat shock response. Mol Cancer Ther. 2008 Oct; 7(10):3256-64.
    View PubMed
  36. Goetz MP, Suman VJ, Couch FJ, Ames MM, Rae JM, Erlander MG, Ma XJ, Sgroi DC, Reynolds CA, Lingle WL, Weinshilboum RM, Flockhart DA, Desta Z, Perez EA, Ingle JN. Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance. Clin Cancer Res. 2008 Sep 15; 14(18):5864-8.
    View PubMed
  37. Gilbert JA, Goetz MP, Reynolds CA, Ingle JN, Giordano KF, Suman VJ, Blair HE, Jenkins RB, Lingle WL, Reinholz MM, Adjei AA, Ames MM. Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy. Mol Cancer Ther. 2008 Apr; 7(4):944-51.
    View PubMed
  38. Visscher DW, Pankratz VS, Santisteban M, Reynolds C, Ristimaki A, Vierkant RA, Lingle WL, Frost MH, Hartmann LC. Association between cyclooxygenase-2 expression in atypical hyperplasia and risk of breast cancer. J Natl Cancer Inst. 2008 Mar 19; 100(6):421-7. Epub 2008 Mar 11.
    View PubMed
  39. Hontz AE, Li SA, Salisbury JL, Lingle WL, Li JJ. Expression of selected Aurora A kinase substrates in solely estrogen-induced ectopic uterine stem cell tumors in the Syrian hamster kidney. Adv Exp Med Biol. 2008; 617:411-8.
    View PubMed
  40. Hartmann LC, Keeney GL, Lingle WL, Christianson TJ, Varghese B, Hillman D, Oberg AL, Low PS. Folate receptor overexpression is associated with poor outcome in breast cancer. Int J Cancer. 2007 Sep 1; 121(5):938-42.
    View PubMed
  41. Degnim AC, Visscher DW, Berman HK, Frost MH, Sellers TA, Vierkant RA, Maloney SD, Pankratz VS, de Groen PC, Lingle WL, Ghosh K, Penheiter L, Tlsty T, Melton LJ 3rd, Reynolds CA, Hartmann LC. Stratification of breast cancer risk in women with atypia: a Mayo cohort study. J Clin Oncol. 2007 Jul 1; 25(19):2671-7. Epub 2007 Jun 11.
    View PubMed
  42. Narita K, Chien J, Mullany SA, Staub J, Qian X, Lingle WL, Shridhar V. Loss of HSulf-1 expression enhances autocrine signaling mediated by amphiregulin in breast cancer. J Biol Chem. 2007 May 11; 282(19):14413-20. Epub 2007 Mar 15.
    View PubMed
  43. Hontz AE, Li SA, Lingle WL, Negron V, Bruzek A, Salisbury JL, Li JJ. Aurora a and B overexpression and centrosome amplification in early estrogen-induced tumor foci in the Syrian hamster kidney: implications for chromosomal instability, aneuploidy, and neoplasia. Cancer Res. 2007 Apr 1; 67(7):2957-63.
    View PubMed
  44. Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Weinshilboum RM, Fritcher EG, Nibbe AM, Desta Z, Nguyen A, Flockhart DA, Perez EA, Ingle JN. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2007 Jan; 101(1):113-21. Epub 2006 Nov 18.
    View PubMed
  45. Gilbert JA, Goetz MP, Reynolds CA, Ingle JN, Giordano KF, Blair HE, Jenkins RB, Lingle WL, Reinholz MM, Adjei AA, Ames MA. Metaplastic breast carcinomas: Increased EGFR gene copy number via aneusomy. Breast Cancer Research and Treatment In Press. 2007.
  46. Perez EA, Suman VJ, Davidson NE, Martino S, Kaufman PA, Lingle WL, Flynn PJ, Ingle JN, Visscher D, Jenkins RB. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol. 2006 Jul 1; 24(19):3032-8.
    View PubMed
  47. Jones MB, Houwink AP, Freeman BK, Greenwood TM, Lafky JM, Lingle WL, Berchuck A, Maxwell GL, Podratz KC, Maihle NJ. The granulin-epithelin precursor is a steroid-regulated growth factor in endometrial cancer. J Soc Gynecol Investig. 2006 May; 13(4):304-11.
    View PubMed
  48. Holmes AL, Wise SS, Sandwick SJ, Lingle WL, Negron VC, Thompson WD, Wise JP Sr. Chronic exposure to lead chromate causes centrosome abnormalities and aneuploidy in human lung cells. Cancer Res. 2006 Apr 15; 66(8):4041-8.
    View PubMed
  49. Goetz MP, Suman VJ, Ingle JN, Nibbe AM, Visscher DW, Reynolds CA, Lingle WL, Erlander M, Ma XJ, Sgroi DC, Perez EA, Couch FJ. A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen. Clin Cancer Res. 2006 Apr 1; 12(7 Pt 1):2080-7.
    View PubMed
  50. Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Weinshilboum RM, Fritcher EGB, Nibbe AM, Desta Z, Nguyen A, Flockhart DA, Perez EA, Ingle JN, 2006. The impact of cytochrome P450 2C6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2006 Jan; 101(1):113-121.
  51. Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Flockhart DA, Desta Z, Perez EA, Ingle JN. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol. 2005 Dec 20; 23(36):9312-8.
    View PubMed
  52. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005 Oct 20; 353(16):1673-84.
    View PubMed
  53. Kelemen LE, Sellers TA, Keeney GL, Lingle WL. Multivitamin and alcohol intake and folate receptor alpha expression in ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2005 Sep; 14(9):2168-72.
    View PubMed
  54. Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K, Vierkant RA, Maloney SD, Pankratz VS, Hillman DW, Suman VJ, Johnson J, Blake C, Tlsty T, Vachon CM, Melton LJ 3rd, Visscher DW. Benign breast disease and the risk of breast cancer. N Engl J Med. 2005 Jul 21; 353(3):229-37.
    View PubMed
  55. Reinholz MM, Nibbe A, Jonart LM, Kitzmann K, Suman VJ, Ingle JN, Houghton R, Zehentner B, Roche PC, Lingle WL. Evaluation of a panel of tumor markers for molecular detection of circulating cancer cells in women with suspected breast cancer. Clin Cancer Res. 2005 May 15; 11(10):3722-32.
    View PubMed
  56. Lingle WL, Lukasiewicz K, Salisbury JL. Deregulation of the centrosome cycle and the origin of chromosomal instability in cancer. Adv Exp Med Biol. 2005; 570:393-421.
    View PubMed
  57. Li JJ, Weroha SJ, Lingle WL, Papa D, Salisbury JL, Li SA. Estrogen mediates Aurora-A overexpression, centrosome amplification, chromosomal instability, and breast cancer in female ACl rats. Proc Natl Acad Sci U S A. 2004 Dec 28; 101(52):18123-8.
    View PubMed
  58. Miller DV, Leontovich AA, Lingle WL, Suman VJ, Mertens ML, Lillie J, Ingalls KA, Perez EA, Ingle JN, Couch FJ, Visscher DW. Utilizing Nottingham Prognostic Index in microarray gene expression profiling of breast carcinomas. Mod Pathol. 2004 Jul; 17(7):756-64.
    View PubMed
  59. Mora GR, Olivier KR, Cheville JC, Mitchell RF, Lingle WL, Tindall DJ. The cytoskeleton differentially localizes the early growth response gene-1 protein in cancer and benign cells of the prostate. Mol Cancer Res. 2004 Feb; 2(2):115-28.
    View PubMed
  60. D'Assoro AB, Lingle WL, Salisbury JL. Centrosome amplification and the development of cancer. Oncogene. 2002 Sep 9; 21(40):6146-53.
    View PubMed
  61. D'Assoro AB, Barrett SL, Folk C, Negron VC, Boeneman K, Busby R, Whitehead C, Stivala F, Lingle WL, Salisbury JL. Amplified centrosomes in breast cancer: A potential indicator of tumor aggressiveness. Breast Cancer Research & Treatment. 2002 Sep; 75(1):25-34.
    View PubMed
  62. Lingle WL, Barrett SL, Negron VC, D'Assoro AB, Boeneman K, Liu W, Whitehead CM, Reynolds C, Salisbury JL. Centrosome amplification drives chromosomal instability in breast tumor development. Proc Natl Acad Sci U S A. 2002 Feb 19; 99(4):1978-83. Epub 2002 Feb 5
    View PubMed
  63. Wang X, Babu JR, Harden JM, Jablonski SA, Gazi MH, Lingle WL, de Groen PC, Yen TJ, van Deursen JM. The mitotic checkpoint protein hBUB3 and the mRNA export factor hRAE1 interact with GLE2p-binding sequence (GLEBS)-containing proteins. J Biol Chem. 2001 Jul 13; 276(28):26559-67. Epub 2001 May 14
    View PubMed
  64. Lutz W, Lingle WL, McCormick D, Greenwood TM, Salisbury JL. Phosphorylation of centrin during the cell cycle and its role in centriole separation preceding centrosome duplication. J Biol Chem. 2001 Jun 8; 276(23):20774-80. Epub 2001 Mar 12
    View PubMed
  65. Lingle WL, Salisbury JL. Methods for the analysis of centrosome reproduction in cancer cells. Methods Cell Biol. 2001; 67:325-36.
    View PubMed
  66. Lingle WL, Salisbury JL. The role of the centrosome in the development of malignant tumors. Curr Top Dev Biol. 2000; 49:313-29.
    View PubMed
  67. Lingle WL, Salisbury JL. Altered centrosome structure is associated with abnormal mitoses in human breast tumors. Am J Pathol. 1999 Dec; 155(6):1941-51.
    View PubMed
  68. Salisbury JL, Lingle WL, White RA, Cordes LE, Barrett S. Microtubule nucleating capacity of centrosomes in tissue sections. Journal of Histochemistry & Cytochemistry. 1999 Oct; 47(10):1265-74.
    View PubMed
  69. Salisbury JL, Whitehead CM, Lingle WL, Barrett SL. Centrosomes and cancer. Biol Cell. 1999 Jul; 91(6):451-60.
    View PubMed
  70. Kumar R, Kobayashi T, Warner GM, Wu Y, Salisbury JL, Lingle W, Pittelkow MR. A novel immediate early response gene, IEX-1, is induced by ultraviolet radiation in human keratinocytes. Biochem Biophys Res Commun. 1998 Dec 18; 253(2):336-41.
    View PubMed
  71. Lingle WL, Lutz WH, Ingle JN, Maihle NJ, Salisbury JL. Centrosome hypertrophy in human breast tumors: implications for genomic stability and cell polarity. Proc Natl Acad Sci U S A. 1998 Mar 17; 95(6):2950-5.
    View PubMed
  72. McManus MJ, Lingle WL, Salisbury JL, Maihle NJ. A transformation-associated complex involving tyrosine kinase signal adapter proteins and caldesmon links v-erbB signaling to actin stress fiber disassembly. Proc Natl Acad Sci U S A. 1997 Oct 14; 94(21):11351-6.
    View PubMed
  73. Lingle WL, Salisbury JL. Centrin and the cytoskeleton of the protist Holomastigotoides. Cell Motil Cytoskeleton. 1997; 36(4):377-90.
    View PubMed
  74. Newell SY, Porter D, Lingle WL. Lignocellulolysis by ascomycetes (fungi) of a saltmarsh grass (smooth cordgrass). Microscopy Research & Technique. 1996 Jan 1; 33(1):32-46.
    View PubMed
  75. Lingle WL, Salisbury JL. Ultrastructure of the parabasalid protist holomas-tigotoides. J Eukaryot Microbiol. 1995 Sep-Oct; 42:490-505.
  76. Ainley WM, McNeil KJ, Hill JW, Lingle WL, Simpson RB, Brenner ML, Nagao RT, Key JL. Regulatable endogenous production of cytokinins up to 'toxic' levels in transgenic plants and plant tissues. Plant Mol Biol. 1993 Apr; 22(1):13-23.
    View PubMed
  77. Roberts JK, Lingle WL, DeSimone N, Dure LS. Cellular concentrations and uniformity of cell-type accumulation of two Lea proteins in cotton embryos. Plant Cell. 1993; 5:769-780.
    View PubMed
  78. Lingle WL, Porter D, O'Kane DJ. Preliminary analysis of genetic complementation of bioluminescence in Panellus stypticus isolated from pine and hardwood. Mycologia. 1992; 84:94-104.
  79. Lingle WL, Clay RP, Porter D. TEM analysis of basidiosporogenesis in Panellus stypticus. Can J Bot. 1992; 70:2017-2027.
  80. Porter D, Lingle WL. Endolithic thraustochytrid marine fungi from planted shell fragments. Mycologia. 1992; 84:289-299.
  81. Lingle WL. Application of freeze substitution fixations for the study of biological samples. The Beam Newsletter of the Southeastern Electron Microscopy Society. 1991; 7:10-16.
  82. O'Kane DJ, Lingle WL, Porter D, Wampler JE. Localization of bioluminescent tissues during basidiocarp development in Panellus stypticus. Mycologia. 1990; 82:595-605.
  83. O'Kane DJ, Lingle WL, Porter D, Wampler JE. Spectral analysis of the bioluminescence of Panellus stypticus. Mycologia. 1990; 82:606-615.
  84. Porter D, Newell SY, Lingle WL. Tunneling bacteria in decaying leaves of the seagrass Thalassia testudinum. Aquatic Botany. 1989; 35:395-401.
  85. Lingle WL. Enhanced staining of the Basidiomycete Panellus stypticus. Cryptogam Bot. 1989; 1:236-242.


Appointments | Contact Us | Give to Mayo Clinic | Search

LEGAL RESTRICTIONS AND TERMS OF USE APPLICABLE TO THIS SITE

Use of this site signifies your agreement to the terms of use.
© 2013 Mayo Foundation for Medical Education and Research. All rights reserved.